華潤醫藥(03320.HK)完成發行20億元公司債
格隆匯1月21日丨華潤醫藥(03320.HK)公吿, 公司的全資附屬公司華潤醫藥控股有限公司收到中國證券監督管理委員會發出關於華潤醫藥控股向專業投資者公開發行公司債券註冊的批覆(《關於同意華潤醫藥控股有限公司向專業投資者公開發行公司債券註冊的批覆》)(證監許可[2022]91號),同意華潤醫藥控股擬議於中華人民共和國向專業投資者公開發行面值總額不超過人民幣100億元的公司債券。批覆自同意註冊日起兩年內有效,華潤醫藥控股可在該期間內分期發行債券。
華潤醫藥控股已於中國發行2022年第一期公司債券,發行規模人民幣20億元,票面利率2.86%,期限三年。本期債券發行所得募集資金將主要用於補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.